Is recruitment more difficult with a placebo arm in randomised controlled trials? A quasirandomised, interview based study
- 24 April 1999
- Vol. 318 (7191) , 1114-1117
- https://doi.org/10.1136/bmj.318.7191.1114
Abstract
Objective: To investigate whether including a placebo arm in a clinical trial of hormone replacement therapy influenced women's stated willingness to participate. Design: Quasirandomised, interview based study. Setting: 10 group practices in the Medical Research Council's General Practice Research Framework. Participants: 436 postmenopausal women aged 45-64 who had not had a hysterectomy. Main outcome measures: Stated willingness to enter a trial and reasons for the decisions made. Results: Of 218 women told about the trial without a placebo arm, 85 (39%) indicated their willingness to enter compared with 65 (30%) of the 218 women told about the trial with the placebo arm (P=0.06). Part of this difference was due to explicit reluctance to take a placebo. Altruism and personal benefit were the reasons most frequently given for wanting to take part in a trial. The reasons most frequently cited for not wanting to take part were reluctance to restart periods, not wanting to take unknown or unnecessary tablets, or not wanting to interfere with present good health. Conclusion: For preventive trials the inclusion of a placebo arm may reduce patients' willingness to participate.Keywords
This publication has 8 references indexed in Scilit:
- Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy. Medical Research Council's General Practice Research Framework.1996
- Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.1995
- Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal WomenJAMA, 1995
- Intentions to use hormone replacement therapy in a community sample of 45-year-old womenMaturitas, 1994
- Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal WomenAnnals of Internal Medicine, 1992
- Postmenopausal Estrogen Therapy and Cardiovascular DiseaseNew England Journal of Medicine, 1991
- Re-evaluating the role of progestogen therapy after the menopause.1988
- Participation in a clinical trial: The patients' point of viewControlled Clinical Trials, 1985